In PDA mouse models, CCR2 inhibition depleted inflammatory monocytes and macrophages, which resulted in enhanced chemotherapy efficacy and anti-tumor T-cell response while inhibiting tumor cell growth and metastasis [42,43]. The gene discussed is CCR2; the disease is Patent ductus arteriosus.